TNF-α-induced VEGF and MMP-9 expression promotes hemorrhagic transformation in pituitary adenomas

Int J Mol Sci. 2011;12(6):4165-79. doi: 10.3390/ijms12064165. Epub 2011 Jun 23.

Abstract

Pituitary apoplexy is a clinical syndrome with unknown pathogenesis. Therefore, identifying the underlying mechanisms is of high clinical relevance. Tumor necrosis factor alpha (TNF-α) is a critical cytokine mediating various hemorrhagic events, but little is known about its involvement in pituitary apoplexy. Here we show that TNF-α may be an important regulator of hemorrhagic transformation in pituitary adenomas. In this study, sixty surgical specimens of hemorrhagic and non-hemorrhagic human pituitary adenomas were examined. Hemorrhagic pituitary adenomas displayed higher protein and mRNA levels of TNF-α, vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) compared with those of non-hemorrhagic tumors. Exposure of MMQ pituitary adenoma cells to TNF-α induced VEGF and MMP-9 expression in vitro. Additionally, TNF-α administration caused hemorrhagic transformation and enhanced VEGF and MMP-9 expression in MMQ pituitary adenoma cell xenografts in mice. Blockers of VEGF or MMP-9, either alone or in combination, attenuated but not abrogated TNF-α mediated hemorrhagic transformation in xenografts. This study suggests that TNF-α may play a role in the development of intratumoral hemorrhage in pituitary adenomas via up-regulation of VEGF and MMP-9.

Keywords: MMP-9; TNF-α; VEGF; intratumoral hemorrhage; pituitary apoplexy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoma / metabolism
  • Adenoma / pathology*
  • Adolescent
  • Adult
  • Angiogenesis Inhibitors / pharmacology
  • Animals
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Bevacizumab
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Female
  • Gene Expression Regulation, Neoplastic* / drug effects
  • Hemorrhage* / genetics
  • Humans
  • Male
  • Matrix Metalloproteinase 9 / chemistry
  • Matrix Metalloproteinase 9 / genetics
  • Matrix Metalloproteinase 9 / metabolism*
  • Mice
  • Mice, Nude
  • Middle Aged
  • Pituitary Neoplasms / metabolism
  • Pituitary Neoplasms / pathology*
  • Rats
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / genetics
  • Recombinant Proteins / pharmacology
  • Transplantation, Heterologous
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / metabolism*
  • Tumor Necrosis Factor-alpha / pharmacology
  • Up-Regulation / drug effects
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / genetics
  • Vascular Endothelial Growth Factor A / metabolism*
  • Young Adult

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Matrix Metalloproteinase 9